RSS-Feed abonnieren
DOI: 10.1055/s-0028-1109862
© Georg Thieme Verlag KG Stuttgart · New York
Neuroendokrine Tumoren des Dünndarms nehmen zu: frühe Tumoren und deren Management
Neuroendocrine Tumors of the Small Bowels are on the Rise: Early Tumors and their ManagementPublikationsverlauf
Manuskript eingetroffen: 29.7.2009
Manuskript akzeptiert: 11.10.2009
Publikationsdatum:
24. Februar 2010 (online)

Zusammenfassung
Neuroendokrine Tumoren (NET) des Dünndarms sind in den letzten 35 Jahren 3- bis 5-fach häufiger geworden. Zeitgleich hat sich die Prognose der Patienten wesentlich verbessert. NET des Duodenums werden häufig „en passant” im Rahmen einer Gastroduodenoskopie diagnostiziert, die unter anderer Fragestellung erfolgt. Dadurch werden die Tumoren in zunehmendem Maße in früheren Stadien festgestellt. Sind sie gut differenziert, nicht funktionell und von bis zu 10 mm Größe, können sie endoskopisch entfernt werden. Eine Operationsindikation besteht dagegen bei gut differenzierten, duodenalen NET von > 20 mm Größe, bei schlecht differenzierten neuroendokrinen Karzinomen und bei sporadischen Gastrinomen. Bei gut differenzierten NET mit einer Größe zwischen 10 und 20 mm als auch bei MEN1-Gastrinomen muss das therapeutische Vorgehen interdisziplinär entschieden werden. Für die Bestimmung der Größe und Infiltrationstiefe der duodenalen NET und zum Nachweis von Lymphknotenmetastasen ist die Endosonografie die Methode der Wahl. Für NET des Ileums ist die Chirurgie die Therapie der Wahl. Bei metastasierten ilealen NET mit hormoneller Symptomatik koupieren stabile Somatostatinanaloga effektiv das Karzinoidsyndrom und führen zudem zu einer signifikanten Verlängerung des (progressionsfreien) Überlebens der Patienten. Therapieempfehlungen für NET-Patienten müssen Tumorbiologie, Tumortyp, Tumorlokalisation, Tumorstadium und die individuelle Situation berücksichtigen.
Abstract
Neuroendocrine tumors (NETs) of the small bowels are on the rise: in the US they have increased by 300 – 500 % in the last 35 years. At the same time their prognosis has been much improved. Most NETs of the duodenum are nowadays detected ”incidentally” and therefore recognized at an early stage. Duodenal NETs that are well differentiated, not larger than 10 mm in greatest dimension and limited to the mucosa/submucosa can be endoscopically resected. In NETs with a size between 10 mm and 20 mm the therapeutic strategy has to be individually discussed. Endoscopic ultrasound is the method of choice to determine tumor size and depth of infiltration. Surgery is indicated for well differentiated duodenal NETs greater than 20 mm, for localized sporadic gastrinomas and for localized poorly differentiated NE cancers. Surgery is also indicated for localized/regional ileal NETs. Advanced ileal NETs with a carcinoid syndrome are treated with stable somatostatin analogs. This treatment also significantly improves the (progression-free) survival in patients with metastatic NETs of the ileum. For optimal NET management tumor biology, type, localization and stage of the neoplasm as well as the individual situation of the patient have to be taken into account.
Schlüsselwörter
Karzinoid - Gastrinom - Duodenum - Ileum - Karzinom - Krebs
Key words
carcinoid - gastrinoma - duodenum - ileum - carcinoma - cancer
Literatur
- 1
Modlin I M, Oberg K, Chung D C. et al .
Gastroenteropancreatic neuroendocrine tumours.
Lancet Oncol.
2008;
9
61-72
MissingFormLabel
- 2
Yao J, Hassan M, Phan A. et al .
One hundred years after „carcinoid”: epidemiology of and prognostic factors for neuroendocrine
tumors in 35,825 cases in the United States.
J Clin Oncol.
2008;
26
3063-3072
MissingFormLabel
- 3
Hauso O, Gustafsson B I, Kidd M. et al .
Neuroendocrine tumor epidemiology: contrasting Norway and North America.
Cancer.
2008;
113
2655-2664
MissingFormLabel
- 4
Hassan M M, Phan A, Li D. et al .
Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study.
Int J Cancer.
2008;
123
867-873
MissingFormLabel
- 5
Jensen R T, Niederle B, Mitry E. et al .
Gastrinoma (duodenal and pancreatic).
Neuroendocrinoloy.
2006;
84
173-182
MissingFormLabel
- 6
Jensen R T, Rindi G, Arnold R. et al .
Well-differentiated duodenal tumor/carcinoma (excluding gastrinomas).
Neuroendocrinoloy.
2006;
84
165-172
MissingFormLabel
- 7
Eriksson B, Klöppel G, Krenning E. et al .
Consensus guidelines for the management of patients with digestive neuroendocrine
tumors – well-differentiated jejunal-ileal tumor/carcinoma.
Neuoendocrinology.
2008;
87
8-19
MissingFormLabel
- 8
Scherübl H, Faiss S, Zeitz M.
Neuroendokrine gastrointestinale Tumore. Diagnostik und Therapie.
Dtsch Med Wochenschr.
2003;
128
S81-S83
MissingFormLabel
- 9
Zar N, Garmo H, Holmberg L. et al .
Long-term survival of patients with small intestinal carcinoid tumors.
World J Surgery.
2004;
28
1163-1168
MissingFormLabel
- 10
Bilimoria K Y, Bentrem D J, Wayne J D. et al .
Small bowel cancer in the United States: changes in epidemiology, treatment, and survival
over the last 20 years.
Ann Surgery.
2009;
249
63-71
MissingFormLabel
- 11
Modlin I, Lye K, Kidd M.
A 5-decade analysis of 13 715 carcinoid tumors.
Cancer.
2003;
97
934-959
MissingFormLabel
- 12
Strosberg J, Gardner N, Kvols L.
Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of
the mid-gut.
Neuroendocrinology.
2009;
89
471-476
MissingFormLabel
- 13
Ito T, Tanaka M, Sasano H. et al .
The neuroendocrine tumor workshop of Japan. Preliminary results of a Japanese nationwide
survey of neuroendocrine gastrointestinal tumors.
J Gastroenterol.
2007;
42
497-500
MissingFormLabel
- 14
Ahlman H, Nilsson O, McNicol A M. et al .
Poorly-differentiated endocrine carcinomas of midgut and hindgut origin.
Neuroendocrinology.
2008;
87
40-46
MissingFormLabel
- 15
Grabowski P, Scherübl H.
Expression of neuroendocrine markers in undifferentiated carcinomas of the gastrointestinal
tract.
J Clin Oncol.
2005;
23
4795-4797
MissingFormLabel
- 16 Solcia E, Klöppel G, Sobin L H. (in collaboration with 9 pathologists from 4 countries). Histological typing of endocrine
tumours. Second Edition. WHO international histological classification of tumours. Berlin; Springer 2000
MissingFormLabel
- 17
Klöppel G, Heitz P U, Capella C. et al .
Pathology and nomenclature of human gastrointestinal neuroendocrine (carcinoid) tumors
and related lesions.
World J Surg.
1996;
20
132-141
MissingFormLabel
- 18
Klöppel G, Rindi G, Anlauf M. et al .
Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors.
Virchows Arch.
2007;
451 Suppl 1
S9-S27
MissingFormLabel
- 19
Rindi G, Klöppel G, Alhman H. et al .
TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading
system.
Virchows Arch.
2006;
449
395-401
MissingFormLabel
- 20
Rindi G, Klöppel G, Couvelard A. et al .
TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including
a grading system.
Virchows Arch.
2007;
451
757-762
MissingFormLabel
- 21
Soga J.
Endocrinocarcinomas (carcinoids and their variants) of the duodenum. An evaluation
of 927 cases.
J Exp Clin Cancer Res.
2003;
22
349-363
MissingFormLabel
- 22
Soga J.
Early-stage carcinoids of the gastrointestinal tract: An analysis of 1914 reported
cases.
Cancer.
2005;
103
1587-1595
MissingFormLabel
- 23
Modlin I M, Champaneria M C, Chan A K. et al .
A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid
pace of no progress.
Am J Gastro.
2007;
102
1464-1473
MissingFormLabel
- 24
Scherübl H, Schaaf L, Raue F. et al .
Hereditäre neuroendokrine gastroenteropankreatische Tumore und multiple endokrine
Neoplasie Typ1. Aktuelle Diagnostik und Therapie.
Dtsch Med Wochenschr.
2004;
129
630-633 und 689 – 692
MissingFormLabel
- 25
Scherübl H, Faiss S, Tschöpe R. et al .
Double-balloon enteroscopy for the detection of midgut carcinoids.
Gastrointest Endosc.
2005;
62
994-995
MissingFormLabel
- 26
Scherübl H.
Options for gastroenteropancreatic neuroendocrine tumours.
Lancet Oncol.
2008;
9
203
MissingFormLabel
- 27
Zimmer T, Scherübl H, Faiss S. et al .
Endoscopic ultrasonography of neuroendocrine tumours.
Digestion.
2000;
62
45-50
MissingFormLabel
- 28
Wiedenmann B, Bäder M, Scherübl H. et al .
Gastroenteropancreatic neuroendocrine tumor imaging with somatostatin-receptor scintigraphy.
Sem Oncology.
1994;
21
29-32
MissingFormLabel
- 29
Hoegerle S, Altehoefer C, Scherübl H. et al .
Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors.
Radiology.
2001;
220
373-380
MissingFormLabel
- 30
Koopmans K, Neels O, Kema I. et al .
Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine
and 11C-5-hydroxy-tryptophan positron emission tomography.
J Clin Oncol.
2008;
26
1489-1495
MissingFormLabel
- 31
Garbrecht N, Anlauf M, Schmitt A. et al .
Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence,
types, biological behavior, association with inherited syndromes, and functional activity.
Endocr Relat Cancer.
2008;
15
229-241
MissingFormLabel
- 32
Nilsson O, Van Cutsem E, Delle Fave G. et al .
Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic).
Neuroendocrinology.
2006;
84
212-215
MissingFormLabel
- 33
Shimizu N, Kaminishi M.
Management of patients with neuroendocrine tumors of the esophagus, stomach, and duodenum.
Nippon Geka Gakki Zasshi.
2008;
109
147-151
MissingFormLabel
- 34
Eriksson J, Stålberg P, Nilsson A. et al .
Surgery and radiofrequency ablation for treatment of liver metastases from midgut
and foregut carcinoids and endocrine pancreatic tumors.
World J Surgery.
2008;
32
930-938
MissingFormLabel
- 35
Kwekkeboom D J, Herder W W, Kam B L. et al .
Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3] octreotate:
toxicity, efficacy, and survival.
J Clin Oncol.
2008;
26
2124-2130
MissingFormLabel
- 36
Kennedy A S, Dezarn W A, McNeillie de P. et al .
Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres:
early results in 148 patients.
Am J Clin Oncol.
2008;
31
271-279
MissingFormLabel
- 37
Steinmüller T, Kianmanesh R, Falconi M. et al .
Consensus guidelines for the management of patients with liver metastases from digestive
(neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary.
Neuroendocrinology.
2008;
87
47-62
MissingFormLabel
- 38
Swärd C, Johanson V, Nierveen van Dijkum E. et al .
Prolonged survival after hepatic artery embolization in patients with midgut carcinoid
syndrome.
Br J Surg.
2009;
96
517-521
MissingFormLabel
- 39
Arnold R, Müller H, Schade-Brittinger C. et al .
Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide
LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut
tumors: A report from the PROMID study group.
J Clin Oncol.
2009;
27
4656-4663
MissingFormLabel
- 40
Höpfner M, Schuppan D, Scherübl H.
Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor
receptors and their signaling pathways: recent advances and future perspectives.
World J Gastroenterology.
2008;
14
2461-2473
MissingFormLabel
- 41
Yao J C, Phan A T, Chang D Z. et al .
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade
neuroendocrine tumors: results of a phase II study.
J Clin Oncol.
2008;
26
4311-4318
MissingFormLabel
- 42
Yao J C, Phan A, Hoff P M. et al .
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random
assignment phase II study of depot octreotide with bevacizumab and pegylated interferon
alpha-2b.
J Clin Oncol.
2008;
26
1316-1323
MissingFormLabel
- 43
Hosokawa O, Miyanaga T, Kaizaki Y. et al .
Decreased death from gastric cancer by endoscopic screening: association with a population-based
cancer registry.
Scand J Gastroenterol.
2008;
43
1112-1115
MissingFormLabel
Prof. Dr. Hans Scherübl
Klinik für Innere Medizin – Gastroenterologie und GI Onkologie, Vivantes Klinikum Am
Urban
Dieffenbachstr. 1
10967 Berlin
Telefon: ++ 49/30/1 30 22 52 01
Fax: ++ 49/30/1 30 22 52 05
eMail: hans.scheruebl@vivantes.de